Disposition of 200000 shares by Richard Christopher of Lexaria Bioscience at 3.92 subject to Rule 16b-3
| LEXX Stock | USD 2.23 0.02 0.90% |
Slightly above 52% of Lexaria Bioscience's investor base is interested to short. The analysis of the overall investor sentiment regarding Lexaria Bioscience Corp suggests that many traders are impartial. Lexaria Bioscience's investing sentiment can be driven by a variety of factors including economic data, Lexaria Bioscience's earnings reports, geopolitical events, and overall market trends.
Lexaria |
Filed transaction by Lexaria Bioscience Corp Officer: Chief Executive Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Lexaria Bioscience Fundamental Analysis
We analyze Lexaria Bioscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lexaria Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lexaria Bioscience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
Lexaria Bioscience is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Lexaria Bioscience Corp Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lexaria Bioscience stock to make a market-neutral strategy. Peer analysis of Lexaria Bioscience could also be used in its relative valuation, which is a method of valuing Lexaria Bioscience by comparing valuation metrics with similar companies.
Peers
Lexaria Bioscience Related Equities
| CNSP | Cns Pharmaceuticals | 10.00 | ||||
| ZURA | Zura Bio | 5.41 | ||||
| PHIO | Phio Pharmaceuticals | 1.15 | ||||
| ICU | LMF Acquisition | 0.98 | ||||
| BDRX | Biodexa Pharmaceticals | 0.25 | ||||
| RNAZ | Transcode Therapeutics | 1.79 | ||||
| SONN | Sonnet Biotherapeutics | 1.89 | ||||
| IMMX | Immix Biopharma | 2.25 | ||||
| REVB | Revelation Biosciences | 3.23 | ||||
| ZVSA | ZyVersa Therapeutics | 8.06 |
Additional Tools for Lexaria Stock Analysis
When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.